董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Scott Burell | 男 | Director | 58 | 10.98万美元 | 0.25 | 2023-09-08 |
| Harel Gadot | 男 | President, Chief Executive Officer and Chairman of the Board | 50 | 191.30万美元 | 32.98 | 2023-09-08 |
| Martin Madden | 男 | Director | 62 | 10.98万美元 | 0.25 | 2023-09-08 |
| Yoseph Bornstein | 男 | Director | 64 | 10.23万美元 | 30.45 | 2023-09-08 |
| Prattipati Laxminarain | 男 | Director | 65 | 9.48万美元 | 0.25 | 2023-09-08 |
| Aileen Stockburger | 女 | Director | 60 | 9.28万美元 | 未持股 | 2023-09-08 |
| Tal Wenderow | 男 | Director | 49 | 9.03万美元 | 未持股 | 2023-09-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Harel Gadot | 男 | President, Chief Executive Officer and Chairman of the Board | 50 | 191.30万美元 | 32.98 | 2023-09-08 |
| Eyal Morag | 男 | Chief Medical Officer | 58 | 60.13万美元 | 未持股 | 2023-09-08 |
| Simon Sharon | 男 | Chief Technology Officer and General Manager, Microbot Israel | 64 | 52.63万美元 | 未持股 | 2023-09-08 |
| Rachel Vaknin | 女 | Chief Financial Officer | 44 | 23.46万美元 | 未持股 | 2023-09-08 |
董事简历
中英对照 | 中文 | 英文- Scott Burell
-
Scott Burell在合并后成为Microbot Medical Inc.的董事。自2018年8月1日起，Burell先生一直担任AIVITA Biomedical，Inc.的首席财务官。AIVITA Biomedical，Inc.是一家总部位于加利福尼亚州欧文市的免疫肿瘤公司，专注于利用治疗和再生药物推进商业和临床阶段计划。从2006年11月到2017年11月出售给因维塔公司（NYSE：NVTA），他是CombiMatrix Corporation（NASDAQ：CBMX）的首席财务官、秘书和财务主管。CombiMatrix Corporation是一家专注于家庭健康的临床分子诊断实验室，专门从事植入前基因筛查、产前诊断、流产分析，和儿童发育障碍。2007年，他成功地领导了CombiMatrix与其前母公司的分拆，并领导了几次成功的公共和私人债务及股权融资交易，以及CombiMatrix在2010年的重组。在此之前，Burell先生自2001年11月起担任CombiMatrix的财务副总裁，并于2001年2月至2001年11月担任其财务总监。从1999年5月至2001年2月首次加入CombiMatrix，Burell先生担任Network Commerce，Inc.（纳斯达克：SPNW）的财务总监，位于西雅图的一家公开交易的技术和信息基础设施公司。在此之前，Burell先生在西雅图安达信审计和商业咨询事务所工作了九年。在担任公共会计期间，Burell先生在高科技和医疗市场与许多公共和私人客户合作，并参与了大量公开发行、分拆、合并和收购。Burell先生于1992年获得华盛顿州注册会计师执照，是一名注册会计师（目前不在职）。他拥有中央华盛顿大学会计和商业金融学理学学士学位。
Scott Burell,became a director of the Company following the Merger. Since August 1, 2018, Mr. Burell has been the Chief Financial Officer and Secretary of AIVITA Biomedical, Inc., an Irvine California-based immuno-oncology company focused on the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. From November 2006 until its sale to Invitae Corp. (NASDAQ: NVTA) in November 2017, he was the Chief Financial Officer, Secretary and Treasurer of CombiMatrix Corporation (NASDAQ: CBMX), a family health-focused clinical molecular diagnostic laboratory specializing in pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. He successfully led the split-off of CombiMatrix in 2007 from its former parent, has led several successful public and private debt and equity financing transactions as well as CombiMatrix's reorganization in 2010. Prior to this, Mr. Burell had served as CombiMatrix's Vice President of Finance since November 2001 and as its Controller from February 2001 to November 2001. From May 1999 to first joining CombiMatrix in February 2001, Mr. Burell was the Controller for Network Commerce, Inc. (NASDAQ: SPNW), a publicly traded technology and information infrastructure company located in Seattle. Prior to this, Mr. Burell spent nine years with Arthur Andersen's Audit and Business Advisory practice in Seattle. During his tenure in public accounting, Mr. Burell worked with many clients, both public and private, in the high-tech and healthcare markets, and was involved in numerous public offerings, spin-offs, mergers and acquisitions. Mr. Burell obtained his Washington state CPA license in 1992 and is a certified public accountant (currently inactive). He holds Bachelor of Science degrees in Accounting and Business Finance from Central Washington University. - Scott Burell在合并后成为Microbot Medical Inc.的董事。自2018年8月1日起，Burell先生一直担任AIVITA Biomedical，Inc.的首席财务官。AIVITA Biomedical，Inc.是一家总部位于加利福尼亚州欧文市的免疫肿瘤公司，专注于利用治疗和再生药物推进商业和临床阶段计划。从2006年11月到2017年11月出售给因维塔公司（NYSE：NVTA），他是CombiMatrix Corporation（NASDAQ：CBMX）的首席财务官、秘书和财务主管。CombiMatrix Corporation是一家专注于家庭健康的临床分子诊断实验室，专门从事植入前基因筛查、产前诊断、流产分析，和儿童发育障碍。2007年，他成功地领导了CombiMatrix与其前母公司的分拆，并领导了几次成功的公共和私人债务及股权融资交易，以及CombiMatrix在2010年的重组。在此之前，Burell先生自2001年11月起担任CombiMatrix的财务副总裁，并于2001年2月至2001年11月担任其财务总监。从1999年5月至2001年2月首次加入CombiMatrix，Burell先生担任Network Commerce，Inc.（纳斯达克：SPNW）的财务总监，位于西雅图的一家公开交易的技术和信息基础设施公司。在此之前，Burell先生在西雅图安达信审计和商业咨询事务所工作了九年。在担任公共会计期间，Burell先生在高科技和医疗市场与许多公共和私人客户合作，并参与了大量公开发行、分拆、合并和收购。Burell先生于1992年获得华盛顿州注册会计师执照，是一名注册会计师（目前不在职）。他拥有中央华盛顿大学会计和商业金融学理学学士学位。
- Scott Burell,became a director of the Company following the Merger. Since August 1, 2018, Mr. Burell has been the Chief Financial Officer and Secretary of AIVITA Biomedical, Inc., an Irvine California-based immuno-oncology company focused on the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. From November 2006 until its sale to Invitae Corp. (NASDAQ: NVTA) in November 2017, he was the Chief Financial Officer, Secretary and Treasurer of CombiMatrix Corporation (NASDAQ: CBMX), a family health-focused clinical molecular diagnostic laboratory specializing in pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. He successfully led the split-off of CombiMatrix in 2007 from its former parent, has led several successful public and private debt and equity financing transactions as well as CombiMatrix's reorganization in 2010. Prior to this, Mr. Burell had served as CombiMatrix's Vice President of Finance since November 2001 and as its Controller from February 2001 to November 2001. From May 1999 to first joining CombiMatrix in February 2001, Mr. Burell was the Controller for Network Commerce, Inc. (NASDAQ: SPNW), a publicly traded technology and information infrastructure company located in Seattle. Prior to this, Mr. Burell spent nine years with Arthur Andersen's Audit and Business Advisory practice in Seattle. During his tenure in public accounting, Mr. Burell worked with many clients, both public and private, in the high-tech and healthcare markets, and was involved in numerous public offerings, spin-offs, mergers and acquisitions. Mr. Burell obtained his Washington state CPA license in 1992 and is a certified public accountant (currently inactive). He holds Bachelor of Science degrees in Accounting and Business Finance from Central Washington University.
- Harel Gadot
-
Harel Gadot在公司全资子公司C&；RD Israel Ltd.与Microbot Medical Ltd.合并并并入Microbot Israel&；后成为该公司总裁、首席执行官和董事会主席，Microbot Israel作为公司的全资子公司幸存（The“；Merger”；）。Gadot先生是Microbot Israel的联合创始人，自Microbot Israel于2010年11月成立以来一直担任Microbot Israel的首席执行官。他自2014年7月起担任Microbot Israel’；的董事会主席。他还担任XACT Robotics Ltd.的董事长，该公司是一家总部位于以色列的私营公司，寻求在微创介入程序（如活检和消融）中开发机器人针头转向的新型平台技术，自2013年8月和Medx Xelerator L.P.，医疗设备和数字健康以色列孵化器，自2016年7月起。从2007年12月到2010年4月，他曾担任Ethicon公司（强生公司）的全球集团营销董事，在那里他曾负责公司的全球战略营销。Gadot先生还在强生公司（Johnson and Johnson）担任管理职位，以及欧洲，中东和非洲以及以色列的领导区域战略职位。从2010年8月到2013年11月Contipi Ltd.被金佰利公司收购，Gadot先生担任Contipi Ltd.的董事。Gadot先生拥有纽约州Loudonville Siena College的商业学士学位和英国曼彻斯特大学（University of Manchester，UK）的工商管理硕士学位。
Harel Gadot,became President, Chief Executive Officer and Chairman of the Company's Board following the consummation of the merger of C&RD Israel Ltd, a wholly owned subsidiary of the Company, with and into Microbot Medical Ltd. ("Microbot Israel"), with Microbot Israel surviving as a wholly owned subsidiary of the Company (the "Merger"). Mr. Gadot is a co-founder of Microbot Israel and has served as Microbot Israel's Chief Executive Officer since Microbot Israel was founded in November 2010. He has been the Chairman of Microbot Israel's board of directors since July 2014. He also serves as the Chairman of XACT Robotics Ltd., an Israel-based private company seeking to develop a novel platform technology for robotic needle steering in minimally invasive interventional procedures such as biopsies and ablations, since August 2013 and MEDX Xelerator L.P., a medical device and digital health Israeli incubator, since July 2016. From December 2007 to April 2010 Mr. Gadot was a Worldwide Group Marketing Director at Ethicon Inc., a Johnson and Johnson Company, where he was responsible for the global strategic marketing of the Company. Mr. Gadot also held management positions, as well as leading regional strategic position for Europe, Middle-East and Africa, as well as In Israel, while at Johnson and Johnson. Mr. Gadot served as director for ConTIPI Ltd. from August 2010 until November 2013 when ConTIPI Ltd. was acquired by Kimberly-Clark Corporation. Mr. Gadot holds a B.Sc. in Business from Siena College, Loudonville NY, and an M.B.A. from the University of Manchester, UK. - Harel Gadot在公司全资子公司C&；RD Israel Ltd.与Microbot Medical Ltd.合并并并入Microbot Israel&；后成为该公司总裁、首席执行官和董事会主席，Microbot Israel作为公司的全资子公司幸存（The“；Merger”；）。Gadot先生是Microbot Israel的联合创始人，自Microbot Israel于2010年11月成立以来一直担任Microbot Israel的首席执行官。他自2014年7月起担任Microbot Israel’；的董事会主席。他还担任XACT Robotics Ltd.的董事长，该公司是一家总部位于以色列的私营公司，寻求在微创介入程序（如活检和消融）中开发机器人针头转向的新型平台技术，自2013年8月和Medx Xelerator L.P.，医疗设备和数字健康以色列孵化器，自2016年7月起。从2007年12月到2010年4月，他曾担任Ethicon公司（强生公司）的全球集团营销董事，在那里他曾负责公司的全球战略营销。Gadot先生还在强生公司（Johnson and Johnson）担任管理职位，以及欧洲，中东和非洲以及以色列的领导区域战略职位。从2010年8月到2013年11月Contipi Ltd.被金佰利公司收购，Gadot先生担任Contipi Ltd.的董事。Gadot先生拥有纽约州Loudonville Siena College的商业学士学位和英国曼彻斯特大学（University of Manchester，UK）的工商管理硕士学位。
- Harel Gadot,became President, Chief Executive Officer and Chairman of the Company's Board following the consummation of the merger of C&RD Israel Ltd, a wholly owned subsidiary of the Company, with and into Microbot Medical Ltd. ("Microbot Israel"), with Microbot Israel surviving as a wholly owned subsidiary of the Company (the "Merger"). Mr. Gadot is a co-founder of Microbot Israel and has served as Microbot Israel's Chief Executive Officer since Microbot Israel was founded in November 2010. He has been the Chairman of Microbot Israel's board of directors since July 2014. He also serves as the Chairman of XACT Robotics Ltd., an Israel-based private company seeking to develop a novel platform technology for robotic needle steering in minimally invasive interventional procedures such as biopsies and ablations, since August 2013 and MEDX Xelerator L.P., a medical device and digital health Israeli incubator, since July 2016. From December 2007 to April 2010 Mr. Gadot was a Worldwide Group Marketing Director at Ethicon Inc., a Johnson and Johnson Company, where he was responsible for the global strategic marketing of the Company. Mr. Gadot also held management positions, as well as leading regional strategic position for Europe, Middle-East and Africa, as well as In Israel, while at Johnson and Johnson. Mr. Gadot served as director for ConTIPI Ltd. from August 2010 until November 2013 when ConTIPI Ltd. was acquired by Kimberly-Clark Corporation. Mr. Gadot holds a B.Sc. in Business from Siena College, Loudonville NY, and an M.B.A. from the University of Manchester, UK.
- Martin Madden
-
Martin Madden，自2017年2月6日起担任公司董事。Madden先生曾于1986年至2017年1月在强生公司及其关联公司担任多个职位，最近于2016年2月至2017年1月担任强生公司公司DePuy Synthes研发Vice President。在此之前，从2015年7月至2016年2月，马登先生是强生公司医疗设备公司的Vice President兼新产品开发。2012年1月至2015年7月，马登先生是强生公司全球外科集团的研发Vice President。Madden先生拥有哥伦比亚大学（Columbia University）工商管理硕士学位，卡内基梅隆大学（Carnegie Mellon University）机械工程硕士学位，以及代顿大学（University of Dayton）机械工程学士学位。
Martin Madden,has been a director of the Company since February 6, 2017. Mr. Madden has held various positions at Johnson & Johnson and its affiliates from 1986 to January 2017, most recently as Vice President, Research & Development of DePuy Synthes, a Johnson & Johnson Company, from February 2016 to January 2017. Prior to that, from July 2015 to February 2016, Mr. Madden was the Vice President, New Product Development of Johnson & Johnson Medical Devices. From January 2012 to July 2015, Mr. Madden was the Vice President, Research & Development of Johnson & Johnson's Global Surgery Group. During his thirty-year tenure with Johnson & Johnson's Medical Device organization, he was an innovator and research leader for nearly every medical device business including Cardiology, Electrophysiology, Peripheral Vascular Surgery, General and Colorectal Surgery, Aesthetics, Orthopaedics, Sports Medicine, Spine, and Trauma. As an executive of Johnson & Johnson, Mr. Madden served on the management boards of Johnson & Johnson's Global Surgery Group, Ethicon, Ethicon Endo-Surgery, DePuy-Synthes, and Cordis, with responsibility for research and development - inclusive of organic and licensed/acquired technology. He was also Chairman of J&J's Medical Device Research Council, with responsibility for talent strategy and technology acceleration. Mr. Madden serves on the Board of Directors of Novocure (NASDAQ: NVCR), a global oncology company, and is an advisor to numerous medical device start-ups. Mr. Madden holds a MBA from Columbia University, a M.S. from Carnegie Mellon University in Mechanical Engineering, and a B.S. from the University of Dayton in Mechanical Engineering. - Martin Madden，自2017年2月6日起担任公司董事。Madden先生曾于1986年至2017年1月在强生公司及其关联公司担任多个职位，最近于2016年2月至2017年1月担任强生公司公司DePuy Synthes研发Vice President。在此之前，从2015年7月至2016年2月，马登先生是强生公司医疗设备公司的Vice President兼新产品开发。2012年1月至2015年7月，马登先生是强生公司全球外科集团的研发Vice President。Madden先生拥有哥伦比亚大学（Columbia University）工商管理硕士学位，卡内基梅隆大学（Carnegie Mellon University）机械工程硕士学位，以及代顿大学（University of Dayton）机械工程学士学位。
- Martin Madden,has been a director of the Company since February 6, 2017. Mr. Madden has held various positions at Johnson & Johnson and its affiliates from 1986 to January 2017, most recently as Vice President, Research & Development of DePuy Synthes, a Johnson & Johnson Company, from February 2016 to January 2017. Prior to that, from July 2015 to February 2016, Mr. Madden was the Vice President, New Product Development of Johnson & Johnson Medical Devices. From January 2012 to July 2015, Mr. Madden was the Vice President, Research & Development of Johnson & Johnson's Global Surgery Group. During his thirty-year tenure with Johnson & Johnson's Medical Device organization, he was an innovator and research leader for nearly every medical device business including Cardiology, Electrophysiology, Peripheral Vascular Surgery, General and Colorectal Surgery, Aesthetics, Orthopaedics, Sports Medicine, Spine, and Trauma. As an executive of Johnson & Johnson, Mr. Madden served on the management boards of Johnson & Johnson's Global Surgery Group, Ethicon, Ethicon Endo-Surgery, DePuy-Synthes, and Cordis, with responsibility for research and development - inclusive of organic and licensed/acquired technology. He was also Chairman of J&J's Medical Device Research Council, with responsibility for talent strategy and technology acceleration. Mr. Madden serves on the Board of Directors of Novocure (NASDAQ: NVCR), a global oncology company, and is an advisor to numerous medical device start-ups. Mr. Madden holds a MBA from Columbia University, a M.S. from Carnegie Mellon University in Mechanical Engineering, and a B.S. from the University of Dayton in Mechanical Engineering.
- Yoseph Bornstein
-
Yoseph Bornstein，在合并后成为公司董事。Bornstein先生是Microbot Israel的联合创始人，并自Microbot Israel于2010年11月成立以来一直担任董事会成员。Bornstein先生于2000年10月创立了生命科学控股集团Shizim Ltd.，并自那时起担任其总裁。Bornstein自2002年1月起担任GCP Clinical Studies Ltd.（以色列一家临床研究服务和教育项目供应商）董事长。他是Biotis Ltd.（生物制药行业的服务公司）的主席（2000年6月以来）。此外，他是Dolphin Medical Ltd.（医疗器械行业的服务公司）的主席（2012年4月以来），以及ASIS Enterprises B.B.G.Ltd.（业务发展公司，专注于创造以色列和日本实体之间的业务联系）的主席（2007年8月以来）。Bornstein先生是XACT Robotics Ltd.的联合创始人和董事，该公司是一家总部位于以色列的私营公司，寻求在微创介入程序中开发机器人针头转向的新型平台技术，并且是Shizimxl Innovation Center的创始人。1992年10月，Bornstein先生创立Pharmateam Ltd.，这是一家以色列公司，专门代表国际制药公司，于2000年被出售。Bornstein先生还是多家其他私人持有的生命科学公司的创始人。Bornstein从2002年9月到2005年2月担任United States-Israel Science&Technology Commission the“；USISTF”；生物技术委员会主席，从2002年9月到2005年2月担任USISTF顾问。他也是ILSI-Israel Life Science Industry Organization（并入IATI）和ITTN-Israel Tech Transfer Organization的创始人。
Yoseph Bornstein,became a director of the Company following the Merger. Mr. Bornstein is a co-founder of Microbot Israel and has been a member of the Board of Directors since Microbot Israel was founded in November 2010. Mr. Bornstein founded Shizim Ltd., a life science holding group in October 2000 and has served as its CEO and director since then. Mr. Bornstein is the Chairman of, and through Shizim owns a stake in: GCP Clinical Studies Ltd., a provider of clinical research services and educational programs in Israel since January 2002; Biotis Ltd., a service company for the bio-pharmaceutical industry, since June 2000; Dolphin Medical Ltd., which supplies the medical device industry, since April 2012, and LSA - Life Science Accelerator Ltd., since 2000. He is the Chairman of ASIS Enterprises B.B.G. Ltd., a business development company focusing on creating business ties between Israeli and Japanese entities, since August 2007. Mr. Bornstein is a co-founder and director of XACT Robotics, which is developing a novel platform technology for robotic needle steering in minimally invasive interventional procedures. In October 1992, Mr. Bornstein founded Pharmateam Ltd., an Israeli company that specialized in representing international pharmaceutical companies which was sold in 2000. Mr. Bornstein is also a founder of a number of other privately held life-science companies. Mr. Bornstein served as the Biotechnology Committee Chairman of the United States-Israel Science & Technology Commission (the "USISTC") from September 2002 to February 2005 as well as a consultant for USISTC from September 2002 to February 2005. He is also the founder of ILSI-Israel Life Science Industry Organization (who was integrated into IATI) and ITTN-Israel Tech Transfer Organization. He founded in July 2014 ShizimXL Ltd., an international medical device innovation center, and founded in January 2020 ShizimVS Ltd., a digital health innovation center. Mr. Bornstein is an external director in Can-fite BioPharma Ltd. (Nasdaq:CANF). - Yoseph Bornstein，在合并后成为公司董事。Bornstein先生是Microbot Israel的联合创始人，并自Microbot Israel于2010年11月成立以来一直担任董事会成员。Bornstein先生于2000年10月创立了生命科学控股集团Shizim Ltd.，并自那时起担任其总裁。Bornstein自2002年1月起担任GCP Clinical Studies Ltd.（以色列一家临床研究服务和教育项目供应商）董事长。他是Biotis Ltd.（生物制药行业的服务公司）的主席（2000年6月以来）。此外，他是Dolphin Medical Ltd.（医疗器械行业的服务公司）的主席（2012年4月以来），以及ASIS Enterprises B.B.G.Ltd.（业务发展公司，专注于创造以色列和日本实体之间的业务联系）的主席（2007年8月以来）。Bornstein先生是XACT Robotics Ltd.的联合创始人和董事，该公司是一家总部位于以色列的私营公司，寻求在微创介入程序中开发机器人针头转向的新型平台技术，并且是Shizimxl Innovation Center的创始人。1992年10月，Bornstein先生创立Pharmateam Ltd.，这是一家以色列公司，专门代表国际制药公司，于2000年被出售。Bornstein先生还是多家其他私人持有的生命科学公司的创始人。Bornstein从2002年9月到2005年2月担任United States-Israel Science&Technology Commission the“；USISTF”；生物技术委员会主席，从2002年9月到2005年2月担任USISTF顾问。他也是ILSI-Israel Life Science Industry Organization（并入IATI）和ITTN-Israel Tech Transfer Organization的创始人。
- Yoseph Bornstein,became a director of the Company following the Merger. Mr. Bornstein is a co-founder of Microbot Israel and has been a member of the Board of Directors since Microbot Israel was founded in November 2010. Mr. Bornstein founded Shizim Ltd., a life science holding group in October 2000 and has served as its CEO and director since then. Mr. Bornstein is the Chairman of, and through Shizim owns a stake in: GCP Clinical Studies Ltd., a provider of clinical research services and educational programs in Israel since January 2002; Biotis Ltd., a service company for the bio-pharmaceutical industry, since June 2000; Dolphin Medical Ltd., which supplies the medical device industry, since April 2012, and LSA - Life Science Accelerator Ltd., since 2000. He is the Chairman of ASIS Enterprises B.B.G. Ltd., a business development company focusing on creating business ties between Israeli and Japanese entities, since August 2007. Mr. Bornstein is a co-founder and director of XACT Robotics, which is developing a novel platform technology for robotic needle steering in minimally invasive interventional procedures. In October 1992, Mr. Bornstein founded Pharmateam Ltd., an Israeli company that specialized in representing international pharmaceutical companies which was sold in 2000. Mr. Bornstein is also a founder of a number of other privately held life-science companies. Mr. Bornstein served as the Biotechnology Committee Chairman of the United States-Israel Science & Technology Commission (the "USISTC") from September 2002 to February 2005 as well as a consultant for USISTC from September 2002 to February 2005. He is also the founder of ILSI-Israel Life Science Industry Organization (who was integrated into IATI) and ITTN-Israel Tech Transfer Organization. He founded in July 2014 ShizimXL Ltd., an international medical device innovation center, and founded in January 2020 ShizimVS Ltd., a digital health innovation center. Mr. Bornstein is an external director in Can-fite BioPharma Ltd. (Nasdaq:CANF).
- Prattipati Laxminarain
-
Prattipati Laxminarain，自2017年12月6日起担任公司董事。从2006年4月至2017年10月，Laxminarain先生担任Codman Neuro的全球总裁，Codman Neuro是一家全球神经外科和神经血管公司，提供脑积水管理，神经重症监护和颅骨手术及其他技术的设备组合，它是强生公司DePuy合成公司的一部分。Laxminarain先生目前是Deinde Medical Corporation的首席执行官，并且是Oculogica Inc.、Millar Inc.和GT Medical Inc.的董事会成员。他获有印度海德拉巴Osmania University的机械工程学位，以及Indian Institute of Management的工商管理硕士学位。
Prattipati Laxminarain,has been a director of the Company since December 6, 2017. From April 2006 through October 2017, Mr. Laxminarain served as Worldwide President at Codman Neuro, a global neurosurgery and neurovascular company that offers a portfolio of devices for hydrocephalus management, neuro intensive care and cranial surgery and other technologies, and which was part of DePuy Synthes Companies of Johnson & Johnson. Mr. Laxminarain is currently the CEO of Deinde Medical Corporation, and is a Board Member of Oculogica Inc., Millar Inc., and GT Medical Inc. He has a degree in Mechanical Engineering from Osmania University, Hyderabad, India and an MBA from Indian Institute of Management. - Prattipati Laxminarain，自2017年12月6日起担任公司董事。从2006年4月至2017年10月，Laxminarain先生担任Codman Neuro的全球总裁，Codman Neuro是一家全球神经外科和神经血管公司，提供脑积水管理，神经重症监护和颅骨手术及其他技术的设备组合，它是强生公司DePuy合成公司的一部分。Laxminarain先生目前是Deinde Medical Corporation的首席执行官，并且是Oculogica Inc.、Millar Inc.和GT Medical Inc.的董事会成员。他获有印度海德拉巴Osmania University的机械工程学位，以及Indian Institute of Management的工商管理硕士学位。
- Prattipati Laxminarain,has been a director of the Company since December 6, 2017. From April 2006 through October 2017, Mr. Laxminarain served as Worldwide President at Codman Neuro, a global neurosurgery and neurovascular company that offers a portfolio of devices for hydrocephalus management, neuro intensive care and cranial surgery and other technologies, and which was part of DePuy Synthes Companies of Johnson & Johnson. Mr. Laxminarain is currently the CEO of Deinde Medical Corporation, and is a Board Member of Oculogica Inc., Millar Inc., and GT Medical Inc. He has a degree in Mechanical Engineering from Osmania University, Hyderabad, India and an MBA from Indian Institute of Management.
- Aileen Stockburger
-
艾琳·斯托克伯格（Aileen Stockburger）于2020年3月26日被董事会任命为董事会成员，以填补董事会空缺并担任公司II类董事，任期自2020年4月1日开始。自2018年2月起，Stockburger女士通过Aileen Stockburger LLC提供并购咨询和咨询服务。在此之前，从1989年到2018年1月，斯托克伯格女士在强生公司担任过多个职位，最近的职位是担任强生公司DePuy Synthes Group的Vice President，负责全球业务发展和战略规划，并担任其全球董事会和集团运营委员会的成员，从2010年到2018年。在该职位上，她监督集团的并购活动，包括交易结构，谈判，合同设计和审查以及交易条款。在加入强生公司之前，斯托克伯格女士在普华永道会计师事务所（PricewaterhouseCoopers）工作了几年，并获得了注册会计师证书。她也是Next Science Limited ASX:NXS的非执行董事，这是一家总部位于澳大利亚悉尼的医疗技术公司，主要专注于其专有技术的开发和持续商业化，以减少基于生物膜的感染对人类健康的影响。Stockburger女士在宾夕法尼亚大学沃顿商学院（Wharton School，University of Pennsylvania）获得工商管理硕士学位和学士学位。
Aileen Stockburger,was appointed by the Board on March 26, 2020 to fill a vacancy on the Board and to serve as a Class II director of the Company, with a term commencing on April 1, 2020. Since February 2018, Ms. Stockburger has provided M&A consulting and advisory services through Aileen Stockburger LLC. Prior to that, from 1989 through January 2018, Ms. Stockburger held various positions in Johnson & Johnson, most recently as Vice President, Worldwide Business Development & Strategic Planning for the DePuy Synthes Group of Johnson & Johnson, and as a member of its Worldwide Board and Group Operating Committee, from 2010-2018. In that role, she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Before joining Johnson & Johnson, Ms. Stockburger spent several years at PriceWaterhouseCoopers, and earned her CPA certification. She is also the Chair of Next Science Limited (ASX: NXS), a medical technology company headquartered in Sydney, Australia, with a primary focus in the development and continued commercialization of its proprietary technology to reduce the impact of biofilm based infections in human health, and Chair of Next Science's Audit Committee. She also serve on the Audit Committee and the People, Culture and Remuneration Committee of the Board of Directors of Next Science Limited. Ms. Stockburger received her MBA and BS from The Wharton School, University of Pennsylvania. - 艾琳·斯托克伯格（Aileen Stockburger）于2020年3月26日被董事会任命为董事会成员，以填补董事会空缺并担任公司II类董事，任期自2020年4月1日开始。自2018年2月起，Stockburger女士通过Aileen Stockburger LLC提供并购咨询和咨询服务。在此之前，从1989年到2018年1月，斯托克伯格女士在强生公司担任过多个职位，最近的职位是担任强生公司DePuy Synthes Group的Vice President，负责全球业务发展和战略规划，并担任其全球董事会和集团运营委员会的成员，从2010年到2018年。在该职位上，她监督集团的并购活动，包括交易结构，谈判，合同设计和审查以及交易条款。在加入强生公司之前，斯托克伯格女士在普华永道会计师事务所（PricewaterhouseCoopers）工作了几年，并获得了注册会计师证书。她也是Next Science Limited ASX:NXS的非执行董事，这是一家总部位于澳大利亚悉尼的医疗技术公司，主要专注于其专有技术的开发和持续商业化，以减少基于生物膜的感染对人类健康的影响。Stockburger女士在宾夕法尼亚大学沃顿商学院（Wharton School，University of Pennsylvania）获得工商管理硕士学位和学士学位。
- Aileen Stockburger,was appointed by the Board on March 26, 2020 to fill a vacancy on the Board and to serve as a Class II director of the Company, with a term commencing on April 1, 2020. Since February 2018, Ms. Stockburger has provided M&A consulting and advisory services through Aileen Stockburger LLC. Prior to that, from 1989 through January 2018, Ms. Stockburger held various positions in Johnson & Johnson, most recently as Vice President, Worldwide Business Development & Strategic Planning for the DePuy Synthes Group of Johnson & Johnson, and as a member of its Worldwide Board and Group Operating Committee, from 2010-2018. In that role, she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Before joining Johnson & Johnson, Ms. Stockburger spent several years at PriceWaterhouseCoopers, and earned her CPA certification. She is also the Chair of Next Science Limited (ASX: NXS), a medical technology company headquartered in Sydney, Australia, with a primary focus in the development and continued commercialization of its proprietary technology to reduce the impact of biofilm based infections in human health, and Chair of Next Science's Audit Committee. She also serve on the Audit Committee and the People, Culture and Remuneration Committee of the Board of Directors of Next Science Limited. Ms. Stockburger received her MBA and BS from The Wharton School, University of Pennsylvania.
- Tal Wenderow
-
Tal Wenderow于2020年7月29日由董事会任命，以填补董事会空缺并担任公司的I类董事，任期自2020年8月1日开始。自2019年2月起，Wenderow先生担任Vocalis Health Inc.的总裁兼首席执行官，该公司是一家AI HealthTech公司，致力于开发声乐生物标志物。此前，Wenderow先生于2002年共同创立了Corindus Vascular Robotics，该公司于2019年被Siemens Healthineers收购，是一家纽约证券交易所上市公司。Wenderow先生曾在Corindus担任多个职位，从创始人、首席执行官和成立之初的董事、执行Vice President产品和业务开发，到最近担任国际和业务开发执行Vice President。Wenderow先生获得工商管理学士学位。以色列海法Technion-Israel Institute of Technology机械工程学位。
Tal Wenderow,was appointed by the Board on July 29, 2020 to fill a vacancy on the Board and to serve as a Class I director of the Company, with a term commencing on August 1, 2020. Since September 2021, Mr. Wenderow serves as the Venture Partner at Genesis MedTech, a global medical device company. Previously, from February 2019, Mr. Wenderow served as the President and CEO of Vocalis Health Inc., an AI healthtech company pioneering the development of vocal biomarkers. Previously, Mr. Wenderow co-founded Corindus Vascular Robotics in 2002, which was a New York Stock Exchange-listed company upon its acquisition by Siemens Healthineers in 2019. Mr. Wenderow held various positions at Corindus from founder, Chief Executive Officer and director at inception, Executive Vice President Product & Business Development to his most recent role as Executive Vice President of International & Business Development. Mr. Wenderow received a B.Sc. in Mechanical Engineering at the Technion - Israel Institute of Technology, Haifa, Israel. - Tal Wenderow于2020年7月29日由董事会任命，以填补董事会空缺并担任公司的I类董事，任期自2020年8月1日开始。自2019年2月起，Wenderow先生担任Vocalis Health Inc.的总裁兼首席执行官，该公司是一家AI HealthTech公司，致力于开发声乐生物标志物。此前，Wenderow先生于2002年共同创立了Corindus Vascular Robotics，该公司于2019年被Siemens Healthineers收购，是一家纽约证券交易所上市公司。Wenderow先生曾在Corindus担任多个职位，从创始人、首席执行官和成立之初的董事、执行Vice President产品和业务开发，到最近担任国际和业务开发执行Vice President。Wenderow先生获得工商管理学士学位。以色列海法Technion-Israel Institute of Technology机械工程学位。
- Tal Wenderow,was appointed by the Board on July 29, 2020 to fill a vacancy on the Board and to serve as a Class I director of the Company, with a term commencing on August 1, 2020. Since September 2021, Mr. Wenderow serves as the Venture Partner at Genesis MedTech, a global medical device company. Previously, from February 2019, Mr. Wenderow served as the President and CEO of Vocalis Health Inc., an AI healthtech company pioneering the development of vocal biomarkers. Previously, Mr. Wenderow co-founded Corindus Vascular Robotics in 2002, which was a New York Stock Exchange-listed company upon its acquisition by Siemens Healthineers in 2019. Mr. Wenderow held various positions at Corindus from founder, Chief Executive Officer and director at inception, Executive Vice President Product & Business Development to his most recent role as Executive Vice President of International & Business Development. Mr. Wenderow received a B.Sc. in Mechanical Engineering at the Technion - Israel Institute of Technology, Haifa, Israel.
高管简历
中英对照 | 中文 | 英文- Harel Gadot
Harel Gadot在公司全资子公司C&；RD Israel Ltd.与Microbot Medical Ltd.合并并并入Microbot Israel&；后成为该公司总裁、首席执行官和董事会主席，Microbot Israel作为公司的全资子公司幸存（The“；Merger”；）。Gadot先生是Microbot Israel的联合创始人，自Microbot Israel于2010年11月成立以来一直担任Microbot Israel的首席执行官。他自2014年7月起担任Microbot Israel’；的董事会主席。他还担任XACT Robotics Ltd.的董事长，该公司是一家总部位于以色列的私营公司，寻求在微创介入程序（如活检和消融）中开发机器人针头转向的新型平台技术，自2013年8月和Medx Xelerator L.P.，医疗设备和数字健康以色列孵化器，自2016年7月起。从2007年12月到2010年4月，他曾担任Ethicon公司（强生公司）的全球集团营销董事，在那里他曾负责公司的全球战略营销。Gadot先生还在强生公司（Johnson and Johnson）担任管理职位，以及欧洲，中东和非洲以及以色列的领导区域战略职位。从2010年8月到2013年11月Contipi Ltd.被金佰利公司收购，Gadot先生担任Contipi Ltd.的董事。Gadot先生拥有纽约州Loudonville Siena College的商业学士学位和英国曼彻斯特大学（University of Manchester，UK）的工商管理硕士学位。
Harel Gadot,became President, Chief Executive Officer and Chairman of the Company's Board following the consummation of the merger of C&RD Israel Ltd, a wholly owned subsidiary of the Company, with and into Microbot Medical Ltd. ("Microbot Israel"), with Microbot Israel surviving as a wholly owned subsidiary of the Company (the "Merger"). Mr. Gadot is a co-founder of Microbot Israel and has served as Microbot Israel's Chief Executive Officer since Microbot Israel was founded in November 2010. He has been the Chairman of Microbot Israel's board of directors since July 2014. He also serves as the Chairman of XACT Robotics Ltd., an Israel-based private company seeking to develop a novel platform technology for robotic needle steering in minimally invasive interventional procedures such as biopsies and ablations, since August 2013 and MEDX Xelerator L.P., a medical device and digital health Israeli incubator, since July 2016. From December 2007 to April 2010 Mr. Gadot was a Worldwide Group Marketing Director at Ethicon Inc., a Johnson and Johnson Company, where he was responsible for the global strategic marketing of the Company. Mr. Gadot also held management positions, as well as leading regional strategic position for Europe, Middle-East and Africa, as well as In Israel, while at Johnson and Johnson. Mr. Gadot served as director for ConTIPI Ltd. from August 2010 until November 2013 when ConTIPI Ltd. was acquired by Kimberly-Clark Corporation. Mr. Gadot holds a B.Sc. in Business from Siena College, Loudonville NY, and an M.B.A. from the University of Manchester, UK.- Harel Gadot在公司全资子公司C&；RD Israel Ltd.与Microbot Medical Ltd.合并并并入Microbot Israel&；后成为该公司总裁、首席执行官和董事会主席，Microbot Israel作为公司的全资子公司幸存（The“；Merger”；）。Gadot先生是Microbot Israel的联合创始人，自Microbot Israel于2010年11月成立以来一直担任Microbot Israel的首席执行官。他自2014年7月起担任Microbot Israel’；的董事会主席。他还担任XACT Robotics Ltd.的董事长，该公司是一家总部位于以色列的私营公司，寻求在微创介入程序（如活检和消融）中开发机器人针头转向的新型平台技术，自2013年8月和Medx Xelerator L.P.，医疗设备和数字健康以色列孵化器，自2016年7月起。从2007年12月到2010年4月，他曾担任Ethicon公司（强生公司）的全球集团营销董事，在那里他曾负责公司的全球战略营销。Gadot先生还在强生公司（Johnson and Johnson）担任管理职位，以及欧洲，中东和非洲以及以色列的领导区域战略职位。从2010年8月到2013年11月Contipi Ltd.被金佰利公司收购，Gadot先生担任Contipi Ltd.的董事。Gadot先生拥有纽约州Loudonville Siena College的商业学士学位和英国曼彻斯特大学（University of Manchester，UK）的工商管理硕士学位。
- Harel Gadot,became President, Chief Executive Officer and Chairman of the Company's Board following the consummation of the merger of C&RD Israel Ltd, a wholly owned subsidiary of the Company, with and into Microbot Medical Ltd. ("Microbot Israel"), with Microbot Israel surviving as a wholly owned subsidiary of the Company (the "Merger"). Mr. Gadot is a co-founder of Microbot Israel and has served as Microbot Israel's Chief Executive Officer since Microbot Israel was founded in November 2010. He has been the Chairman of Microbot Israel's board of directors since July 2014. He also serves as the Chairman of XACT Robotics Ltd., an Israel-based private company seeking to develop a novel platform technology for robotic needle steering in minimally invasive interventional procedures such as biopsies and ablations, since August 2013 and MEDX Xelerator L.P., a medical device and digital health Israeli incubator, since July 2016. From December 2007 to April 2010 Mr. Gadot was a Worldwide Group Marketing Director at Ethicon Inc., a Johnson and Johnson Company, where he was responsible for the global strategic marketing of the Company. Mr. Gadot also held management positions, as well as leading regional strategic position for Europe, Middle-East and Africa, as well as In Israel, while at Johnson and Johnson. Mr. Gadot served as director for ConTIPI Ltd. from August 2010 until November 2013 when ConTIPI Ltd. was acquired by Kimberly-Clark Corporation. Mr. Gadot holds a B.Sc. in Business from Siena College, Loudonville NY, and an M.B.A. from the University of Manchester, UK.
- Eyal Morag
Eyal Morag自2020年5月起担任公司首席医疗官。作为CMO，Morag博士将领导公司临床战略的开发和执行，包括其SCS和Liberty产品的当前开发及其未来的管道。Morag博士自2017年11月1日起担任公司科学顾问委员会成员。Morag博士获得美国放射学委员会的认证，并于2017年3月至2020年5月担任以色列阿什杜德市Assuta Ashdod Medical Center的放射学主席。此前，他曾担任URG Teleradiology LLC（新泽西最大的亚专科放射学和远程放射学服务提供商）的高级放射学家（2014年7月至2017年3月）。他是波士顿大学医学院（Boston University School of Medicine）的毕业生，并在贝斯以色列女执事医疗中心和哈佛医学院（the Beth Israel Deaconess Medical Center&Harvard Medical School）完成了他的放射学住院医师和心血管和介入放射学研究金。在接受临床培训后，Morag博士随后加入马萨诸塞州西部的一家私人诊所，在那里他曾担任Holyoke Medical Center放射科主任数年。他也曾担任Mercy Health Partners Hospitals（位于俄亥俄州托莱多）的区域放射学董事，也曾担任the University Radiology Group的成员，在那里他曾领导风险投资部门的国际投资工作。Morag&8217；博士开发和建立放射学相关业务的国际经验包括远程放射学，介入放射学服务和独立的成像中心。在他的奖学金期间，Morag博士共同创立了Intek Technology，一家医疗设备创业公司。后来他创立了Global Versa Radiology（“；GVR”；），这是一家位于以色列和美国的远程放射学公司。GVR在俄罗斯和乌克兰建立了影像中心，并在美国和以色列以外的国家提供远程放射学服务。Morag博士担任GVR&8217；的首席医疗官和副总裁。他继续参与从AI到医疗设备的几家创业公司。Morag博士还是Medx Xelerator的顾问委员会成员，该公司是一家医疗设备和数字健康孵化器，Gadot先生是该公司的董事长。
Eyal Morag,has served as the Company's Chief Medical Officer ("CMO") since May 2020 and resigned as such on August 29, 2023 effective November 29, 2023. As CMO, Dr. Morag leads the development and execution of the clinical strategy of the Company, including its current development of the SCS and LIBERTY products as well as its future pipeline. Dr. Morag is a member of the Company's Scientific Advisory Board since November 1, 2017. Dr. Morag is certified by the American Board of Radiology, and from March 2017 through May 2020 has been the Chairman of Radiology at Assuta Ashdod Medical Center, Ashdod, Israel. Previously, from July 2014 through March 2017, he was the senior Radiologist at URG Teleradiology LLC, the largest provider of subspecialty radiology and teleradiology services in New Jersey. He is a graduate of Boston University School of Medicine and completed both his Radiology residency and Fellowship in Cardiovascular & Interventional Radiology at the Beth Israel Deaconess Medical Center & Harvard Medical School. Following his clinical training, Dr. Morag then joined a private practice in western Massachusetts, where he served as Chief of Radiology at Holyoke Medical Center for several years. He has also served as the Regional Radiology Director at Mercy Health Partners Hospitals in Toledo, Ohio, and was a member of the University Radiology Group where he headed the International Investment efforts for the Ventures division. Dr. Morag's international experience developing and establishing radiology-related businesses includes teleradiology, interventional Radiology services, and free-standing imaging centers. During his fellowship, Dr. Morag co-founded InTek Technology, a medical device startup company. Later he founded Global Versa Radiology ("GVR"), an Israeli and U.S. based teleradiology company. GVR has established imaging centers in Russia and Ukraine and provided teleradiology services in countries outside the U.S. and Israel. Dr. Morag served as GVR's Chief Medical Officer and Vice-President. He continues to be involved in several startup companies ranging from AI to medical devices. Dr. Morag is also a member of the Advisory Board of MEDX Xelerator, a medical device and digital health incubator, of which Mr. Gadot is Chairman.- Eyal Morag自2020年5月起担任公司首席医疗官。作为CMO，Morag博士将领导公司临床战略的开发和执行，包括其SCS和Liberty产品的当前开发及其未来的管道。Morag博士自2017年11月1日起担任公司科学顾问委员会成员。Morag博士获得美国放射学委员会的认证，并于2017年3月至2020年5月担任以色列阿什杜德市Assuta Ashdod Medical Center的放射学主席。此前，他曾担任URG Teleradiology LLC（新泽西最大的亚专科放射学和远程放射学服务提供商）的高级放射学家（2014年7月至2017年3月）。他是波士顿大学医学院（Boston University School of Medicine）的毕业生，并在贝斯以色列女执事医疗中心和哈佛医学院（the Beth Israel Deaconess Medical Center&Harvard Medical School）完成了他的放射学住院医师和心血管和介入放射学研究金。在接受临床培训后，Morag博士随后加入马萨诸塞州西部的一家私人诊所，在那里他曾担任Holyoke Medical Center放射科主任数年。他也曾担任Mercy Health Partners Hospitals（位于俄亥俄州托莱多）的区域放射学董事，也曾担任the University Radiology Group的成员，在那里他曾领导风险投资部门的国际投资工作。Morag&8217；博士开发和建立放射学相关业务的国际经验包括远程放射学，介入放射学服务和独立的成像中心。在他的奖学金期间，Morag博士共同创立了Intek Technology，一家医疗设备创业公司。后来他创立了Global Versa Radiology（“；GVR”；），这是一家位于以色列和美国的远程放射学公司。GVR在俄罗斯和乌克兰建立了影像中心，并在美国和以色列以外的国家提供远程放射学服务。Morag博士担任GVR&8217；的首席医疗官和副总裁。他继续参与从AI到医疗设备的几家创业公司。Morag博士还是Medx Xelerator的顾问委员会成员，该公司是一家医疗设备和数字健康孵化器，Gadot先生是该公司的董事长。
- Eyal Morag,has served as the Company's Chief Medical Officer ("CMO") since May 2020 and resigned as such on August 29, 2023 effective November 29, 2023. As CMO, Dr. Morag leads the development and execution of the clinical strategy of the Company, including its current development of the SCS and LIBERTY products as well as its future pipeline. Dr. Morag is a member of the Company's Scientific Advisory Board since November 1, 2017. Dr. Morag is certified by the American Board of Radiology, and from March 2017 through May 2020 has been the Chairman of Radiology at Assuta Ashdod Medical Center, Ashdod, Israel. Previously, from July 2014 through March 2017, he was the senior Radiologist at URG Teleradiology LLC, the largest provider of subspecialty radiology and teleradiology services in New Jersey. He is a graduate of Boston University School of Medicine and completed both his Radiology residency and Fellowship in Cardiovascular & Interventional Radiology at the Beth Israel Deaconess Medical Center & Harvard Medical School. Following his clinical training, Dr. Morag then joined a private practice in western Massachusetts, where he served as Chief of Radiology at Holyoke Medical Center for several years. He has also served as the Regional Radiology Director at Mercy Health Partners Hospitals in Toledo, Ohio, and was a member of the University Radiology Group where he headed the International Investment efforts for the Ventures division. Dr. Morag's international experience developing and establishing radiology-related businesses includes teleradiology, interventional Radiology services, and free-standing imaging centers. During his fellowship, Dr. Morag co-founded InTek Technology, a medical device startup company. Later he founded Global Versa Radiology ("GVR"), an Israeli and U.S. based teleradiology company. GVR has established imaging centers in Russia and Ukraine and provided teleradiology services in countries outside the U.S. and Israel. Dr. Morag served as GVR's Chief Medical Officer and Vice-President. He continues to be involved in several startup companies ranging from AI to medical devices. Dr. Morag is also a member of the Advisory Board of MEDX Xelerator, a medical device and digital health incubator, of which Mr. Gadot is Chairman.
- Simon Sharon
Simon Sharon自2018年4月起担任公司首席技术官，自2021年4月起担任Microbot Israel总经理。从2016年8月到2018年3月，Sharon先生担任Medx Xelerator的首席技术官，这是一家以色列医疗设备和数字健康孵化器。他也是Xact Robotics Ltd.的董事，该公司是一家以色列私营公司，开发一种新型平台机器人技术，用于微创介入手术中的指针转向。Harel Gadot先生是公司的总裁、首席执行官和董事长，是Xact和Medx Xelerator的董事长。在此之前，Sharon先生于2013年2月至2016年8月在Microbot Israel成为上市公司之前担任首席运营官。在加入Microbot Israel之前，Sharon先生是Icecure Medical（一家TASE贸易公司，开发低温消融系统的投资组合）的研发副总裁。在加入Icecure之前，他在Rockwell Automation-Anorad Israel Ltd.担任越来越多的职务，这是一家领先的基于线性马达的精密定位设备制造商。在加入Rockwell之前，Sharon先生是Disc-O-Tech Medical Technologies Ltd.的研发经理，Disc-O-Tech Medical Technologies Ltd.是一家私人骨科企业，被Kyphon收购，目前是Medtronic的一部分，在此之前，Sharon先生是CI Systems的研发经理，世界范围内广泛供应各种电光测试和测量设备.
Simon Sharon,has served as the Company's Chief Technology Officer since April 2018 and as the General Manager of Microbot Israel since April 2021. From August 2016 to March 2018, Mr. Sharon served as the Chief Technology Officer at MEDX Xelerator, an Israel-based medical device and digital health incubator. He is also a director of XACT Robotics Ltd., a private Israeli company developing a novel platform robotic technology for needle steering in minimally invasive interventional procedures. Mr. Harel Gadot, the Company's President, CEO and Chairman, is the Chairman of each of XACT and MEDX Xelerator. Prior to this, Mr. Sharon held the position of Chief Operating Officer at Microbot Israel before it became a publicly traded company from February 2013 to August 2016. Prior to joining Microbot Israel, Mr. Sharon was the Vice President of Research & Development with IceCure Medical, a TASE traded company developing a portfolio of cryogenic ablation systems. Prior to IceCure, he held roles of increasing responsibility at Rockwell Automation-Anorad Israel Ltd., a leading linear motor-based, precision positioning equipment manufacturer. Prior to Rockwell, Mr. Sharon was the Research & Development Manager at Disc-O-Tech Medical Technologies Ltd., a private orthopedic venture that was acquired by Kyphon (currently part of Medtronic), and before this was the Research & Development Manager at CI Systems, a worldwide supplier of a wide range of electro-optical test and measurement equipment.- Simon Sharon自2018年4月起担任公司首席技术官，自2021年4月起担任Microbot Israel总经理。从2016年8月到2018年3月，Sharon先生担任Medx Xelerator的首席技术官，这是一家以色列医疗设备和数字健康孵化器。他也是Xact Robotics Ltd.的董事，该公司是一家以色列私营公司，开发一种新型平台机器人技术，用于微创介入手术中的指针转向。Harel Gadot先生是公司的总裁、首席执行官和董事长，是Xact和Medx Xelerator的董事长。在此之前，Sharon先生于2013年2月至2016年8月在Microbot Israel成为上市公司之前担任首席运营官。在加入Microbot Israel之前，Sharon先生是Icecure Medical（一家TASE贸易公司，开发低温消融系统的投资组合）的研发副总裁。在加入Icecure之前，他在Rockwell Automation-Anorad Israel Ltd.担任越来越多的职务，这是一家领先的基于线性马达的精密定位设备制造商。在加入Rockwell之前，Sharon先生是Disc-O-Tech Medical Technologies Ltd.的研发经理，Disc-O-Tech Medical Technologies Ltd.是一家私人骨科企业，被Kyphon收购，目前是Medtronic的一部分，在此之前，Sharon先生是CI Systems的研发经理，世界范围内广泛供应各种电光测试和测量设备.
- Simon Sharon,has served as the Company's Chief Technology Officer since April 2018 and as the General Manager of Microbot Israel since April 2021. From August 2016 to March 2018, Mr. Sharon served as the Chief Technology Officer at MEDX Xelerator, an Israel-based medical device and digital health incubator. He is also a director of XACT Robotics Ltd., a private Israeli company developing a novel platform robotic technology for needle steering in minimally invasive interventional procedures. Mr. Harel Gadot, the Company's President, CEO and Chairman, is the Chairman of each of XACT and MEDX Xelerator. Prior to this, Mr. Sharon held the position of Chief Operating Officer at Microbot Israel before it became a publicly traded company from February 2013 to August 2016. Prior to joining Microbot Israel, Mr. Sharon was the Vice President of Research & Development with IceCure Medical, a TASE traded company developing a portfolio of cryogenic ablation systems. Prior to IceCure, he held roles of increasing responsibility at Rockwell Automation-Anorad Israel Ltd., a leading linear motor-based, precision positioning equipment manufacturer. Prior to Rockwell, Mr. Sharon was the Research & Development Manager at Disc-O-Tech Medical Technologies Ltd., a private orthopedic venture that was acquired by Kyphon (currently part of Medtronic), and before this was the Research & Development Manager at CI Systems, a worldwide supplier of a wide range of electro-optical test and measurement equipment.
- Rachel Vaknin
Rachel Vaknin，自2022年4月起担任公司首席财务官，在此之前自2022年1月起担任公司财务副总裁。2017年9月至2021年12月，Vaknin女士担任以色列-美国自主技术软件供应商Imagry的首席财务官。从2004年4月至2016年12月，Vaknin女士担任迈勒罗斯科技有限公司的FP & A部门经理，该公司是一家以色列-美国跨国计算机网络产品供应商，于2020年被英伟达收购。在该公司，除其他外，她负责预算规划、预算控制、建立和维护商业情报关键绩效指标、领导团队编制季度财务报表、获取和管理赠款以及萨班斯-奥克斯利控制。
Rachel Vaknin,has served as the Company's Chief Financial Officer since April 2022 and before that was its VP Finance since January 2022. From September 2017 to December 2021, Ms. Vaknin served as the Chief Financial Officer at Imagry, an Israeli-American autonomous technologies software provider. From April 2004 through December 2016, Ms. Vaknin was the FP&A Department Manager at Mellanox Technologies Ltd., an Israeli-American multinational supplier of computer networking products acquired by Nvidia in 2020, where she was responsible, among other things, for budget planning, budget control, building and maintaining business intelligence key performance indicators, leading teams with respect to preparing quarterly financial statements, obtaining and managing grant monies, and Sarbanes-Oxley controls.- Rachel Vaknin，自2022年4月起担任公司首席财务官，在此之前自2022年1月起担任公司财务副总裁。2017年9月至2021年12月，Vaknin女士担任以色列-美国自主技术软件供应商Imagry的首席财务官。从2004年4月至2016年12月，Vaknin女士担任迈勒罗斯科技有限公司的FP & A部门经理，该公司是一家以色列-美国跨国计算机网络产品供应商，于2020年被英伟达收购。在该公司，除其他外，她负责预算规划、预算控制、建立和维护商业情报关键绩效指标、领导团队编制季度财务报表、获取和管理赠款以及萨班斯-奥克斯利控制。
- Rachel Vaknin,has served as the Company's Chief Financial Officer since April 2022 and before that was its VP Finance since January 2022. From September 2017 to December 2021, Ms. Vaknin served as the Chief Financial Officer at Imagry, an Israeli-American autonomous technologies software provider. From April 2004 through December 2016, Ms. Vaknin was the FP&A Department Manager at Mellanox Technologies Ltd., an Israeli-American multinational supplier of computer networking products acquired by Nvidia in 2020, where she was responsible, among other things, for budget planning, budget control, building and maintaining business intelligence key performance indicators, leading teams with respect to preparing quarterly financial statements, obtaining and managing grant monies, and Sarbanes-Oxley controls.